BROOKS · NSE
Brooks Laboratories Limited
₹61
+3.23% (+₹1.91)
Prev. close
₹59.09
Volume
78,607
Delivery %
49.8%
As of
23 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Brooks Laboratories Limited
Brooks Laboratories Limited operates as a pharmaceutical manufacturer in India and internationally. It operates in two segments, Manufacturing and Trading. The company offers liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; and B-Lactam and cephalosporin tablets, dry powder syrups, and injections. It is also involved in loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries; and trading in pharmaceutical products, ingredients, and intermediaries. In addition, the company offers oncology products and hormonal injections; and formulations for therapeutic areas comprising antibiotic, pain management, controlled drugs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan, Nigeria, Lebanon, Mauritius, Sudan, Madagascar, the Democratic Republic of Congo, Angola, Mozambique, Latin America, and Africa. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Prashant Rathi
Headquarters
Mumbai
Employees
347
Website
brookslabs.netExchange
View on NSE ↗Key stats
Market cap
₹179.69 Cr
P/E ratio (TTM)
13.6
EPS (TTM)
₹4.49
Beta (1Y · daily vs NIFTY 50)
1.60
Beta (5Y · monthly vs NIFTY 50)
2.10
Shares float
1.33 Cr
EPS · quarter ended Jun 2026
₹-0.61
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹77.25 Cr | ₹91.08 Cr | ₹63.20 Cr | ₹79.01 Cr | ₹82.56 Cr | ₹85.74 Cr | |
| EBITDA | ₹1.26 Cr | ₹-13.45 Cr | ₹-29.39 Cr | ₹-17.07 Cr | ₹-7.34 Cr | ₹26.89 Cr |
| ₹-19.38 Cr | ₹-16.19 Cr | ₹-20.89 Cr | ₹-19.59 Cr | ₹-9.97 Cr | ₹24.58 Cr | |
| Diluted EPS | ₹6.31 | ₹-7.82 | ₹-12.57 | ₹-7.67 | ₹-3.72 | ₹8.35 |
Total expenses (as filed), Employee benefit expense, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹162.00 Cr | ₹196.00 Cr | ₹110.00 Cr | ₹90.00 Cr | ₹124.00 Cr | ₹148.00 Cr | |
| — | — | ₹6.51 Cr | ₹5.64 Cr | ₹7.58 Cr | ₹8.52 Cr | |
| Stockholders' equity | ₹79.00 Cr | ₹88.00 Cr | ₹74.00 Cr | ₹65.00 Cr | ₹98.00 Cr | ₹122.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹4.46 Cr | ₹-37.44 Cr | ₹-14.49 Cr | ₹-9.80 Cr | ₹2.63 Cr | ₹9.29 Cr | |
| Investing cash flow | ₹-5.13 Cr | ₹-24.91 Cr | ₹49.47 L | ₹18.22 L | ₹-45.97 Cr | ₹-2.92 Cr |
| ₹1.16 Cr | ₹64.07 Cr | ₹11.41 Cr | ₹9.72 Cr | ₹43.36 Cr | ₹17.09 L | |
| Capital expenditure | ₹-5.61 Cr | ₹-27.62 Cr | ₹-47.00 L | ₹-44.00 L | ₹-92.00 L | ₹-3.51 Cr |
| End cash position | ₹88.39 L | ₹2.61 Cr | ₹2.33 L | ₹12.55 L | ₹4.34 L | ₹6.59 Cr |
Dividends paid has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Brooks Laboratories Limited | ₹181.25 Cr | ₹59.09 | 13.7 | 1.48 | 20.0% | 0.07 | +3.9% | -60.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 16
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Brooks Laboratories Share Price rises 8.56% to Rs 69.01
Brooks Laboratories Ltd. (BROOKS) share price increased by 8.56% to Rs 69.01, up from its previous close of Rs 63.57. The company's market capitalization reached Rs 187.47 crore. This movement puts BROOKS in focus as a notable stock in today's market.